Related Experiment Video
Updated: Aug 15, 2025
Author Spotlight: High-Quality Quantum Dot Nanobeads for Sensitive Fluorescent Lateral Flow Immunoassays
Published on: June 28, 2024
NIR-II fluorescent nanoprobe-labeled lateral flow biosensing platform: A high-performance point-of-care testing for
Zhaorui Song1, Yongkuan Suo2, Shuang Duan3
1Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong, 264117, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Abstract:
Fluorescent lateral flow immunoassay (LFA) is one of the most common analytical platforms for point-of-care testing (POCT), which is capable of facile and early screening of biomarkers. Notably, fluorescent probes play a decisive role in analytical performances of LFA. Herein, we report a novel LFA based on the rare earth doped nanoparticles (RENPs) emitting in the second near-infrared (NIR-II) window for the detection of biomarkers, such as carcinoembryonic antigen (CEA). Benefiting from the dual fluorescent emission at NIR-II window, strong fluorescent penetration, low autofluorescence and excellent photostability of RENPs, this proposed NIR-II LFA displays a good linear relationship ranging from 1 to 320 ng mL-1. The detection limit is as low as 0.37 ng mL-1, which is of 13.5 times lower than the clinical cutoff value. Overall, NIR-II LFA biosensing platform based RENPs not only exhibits high sensitivity, accuracy and specificity, but also have characteristics of rapidity, simplicity and low cost. It holds high potential for early diagnosis of tumor biomarkers in POCT.
